Luteolin, Tretinoin, and Brusatol are examples of anti-Nrf2 agents used by various studies to augment CLL cells’ sensitivity to cytotoxic drugs including doxorubicin, arsenic trioxide, and etoposide respectively [72–74]. This evidence concerns the gene NFE2L2 and B-cell chronic lymphocytic leukemia.